Browse > Article
http://dx.doi.org/10.7314/APJCP.2014.15.8.3503

Correlations Between Serum IL33 and Tumor Development: a Meta-analysis  

Chen, Xiang-Jun (Department of Medical Quality Control, West China Hospital, Sichuan University)
Huang, Ying-De (Department of Medical Quality Control, West China Hospital, Sichuan University)
Li, Nian (Department of Medical Quality Control, West China Hospital, Sichuan University)
Chen, Min (Department of Medical Quality Control, West China Hospital, Sichuan University)
Liu, Fang (Department of Medical Quality Control, West China Hospital, Sichuan University)
Pu, Dan (Clinical Skill Experiment Teaching Center, West China Hospital, Sichuan University)
Zhou, Tao-You (Department of Infectious Disease, West China Hospital, Sichuan University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.15, no.8, 2014 , pp. 3503-3505 More about this Journal
Abstract
Background: Interleukin-33 (IL-33) has recently been implicated in tumor development. Methods: Data was obtained from PubMed, EMBASE, Clinical trial, Cochrane Library, Web of Science, CNKI and Wanfang databases. After quality assessment and data extraction, a meta-analysis was performed using Review Manager 5.2 software. Results: There were eight documents included in this meta-analysis. The results showed IL33 levels to be higher in tumor patients than that in health people, but no correlations tumor stage, metastasis and survival time of tumor patients were evident. Conclusion: IL33 may be useful as an alarm factor in tumor detection and prognosis.
Keywords
IL33; tumor; meta-analysis;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Williams MA, Bevan MJ (2007). Effector and memory CTL differentiation, Annu Rev Immunol, 25, 171-92.   DOI   ScienceOn
2 Schmitz J, Owyang A, Oldham E, et al (2005). IL-33, an interleukin-1-likecytokine that signals via the IL-1 receptorrelated protein ST2 and induces Thelper type 2-associated cytokines. Immunity, 23, 479–90.   DOI   ScienceOn
3 Sun P, Ben Q, Tu S, et al (2011). Serum interleukin-33 levels in patients with gastric cancer. Dig Dis Sci, 56, 3596-601.   DOI   ScienceOn
4 Walzl G, Matthews S, Kendall S, et al (2001). Inhibition of T1/ST2 during respiratory syncytial virus infection prevents T helper cell type 2 (Th2)-but not Th1-driven immunopathology. J Exp Med, 193, 785-92.   DOI
5 Zhang P, Liu XK, Chu Z, et al (2012). Detection of interleukin-33 in serum and carcinoma tissue from patients with hepatocellular carcinoma and its clinical implications. J Int Med Res, 40, 1654-61.   DOI
6 Kakkar R and Lee RT (2008). The IL-33/ST2 pathway:therapeutic target and novel biomarker. Nat Rev Drug Discov, 7, 827–40.   DOI   ScienceOn
7 Humphreys NE, Xu D, Hepworth MR, et al (2008). IL-33, a potent inducer of adaptive immunity to intestinal nematodes. J Immunol, 180, 2443-9.   DOI
8 Jovanovic IP, Pejnovic NN, Radosavljevic GD, et al (2014). Interleukin-33/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cells. Int J Cancer, 134, 1669-82.   DOI   ScienceOn
9 Jovanovic I, Radosavljevic G, Mitrovic M, et al (2011). ST2 deletion enhances innate and acquired immunity to murine mammary carcinoma. Eur J Immuno, l41, 1902-12.   DOI   ScienceOn
10 Liew FY, Pitman N, McInnes IB (2010). Disease-associated functions of IL-33: the new kid in the IL-1 family, Nat Rev Immunol, 10, 103-10.   DOI   ScienceOn
11 Lopetuso LR, Scaldaferri F, Pizarro TT (2012). Emerging role of the interleukin (IL)-33/ST2 axis in gut mucosal wound healing and fibrosis. Fibrogenesis Tissue Repair, 5, 18.   DOI   ScienceOn
12 Naumnik W, Naumnik B, Niewiarowska K, et al (2012). Novel cytokines: IL-27, IL-29, IL-31 and IL-33. Can they be useful in clinical practice at the time diagnosis of lung cancer?Exp Oncol, 34, 348-53.
13 Oshikawa K, Yanagisawa K, Ohno S, et al (2002). Expression of ST2 in helper T lymphocytes of malignant pleural effusions. Am J Respir Crit Care Med, 165, 1005-9.   DOI   ScienceOn
14 Roy A, Ganesh G, Sippola H, et al (2014). Mast Cell Chymase Degrades the Alarmins Heat Shock Protein 70, Biglycan, HMGB1, and Interleukin-33 (IL-33). and Limits Dangerinduced Inflammation. J Biol Chem, 289, 237-50.   DOI   ScienceOn
15 Santulli P, Even M, Chouzenoux S, et al (2013). Profibrotic interleukin-33 is correlated with uterine leiomyoma tumour burden. Hum Reprod, 28, 2126-33.   DOI   ScienceOn
16 Bourgeois E, Van LP, Samson M, et al (2009). The pro-Th2 cytokine IL-33 directly interacts with invariant NKT and NK cells to induce IFN-gamma production. Eur J Immunol, 39, 1046–55.   DOI   ScienceOn
17 Arshad MI, Piquet-Pellorce C, Samson M (2012). IL-33 and HMGB1 alarmins: sensors of cellular death and their involvement in liver pathology. Liver Int, 32, 1200-10.   DOI   ScienceOn
18 Bergis D, Kassis V, Ranglack A, et al (2013). High serum levels of the interleukin-33 receptor soluble ST2 as a negative prognostic factor in hepatocellular carcinoma. Transl Oncol, 6, 311-8.   DOI
19 Bonilla WV, Frohlich A, Senn K, et al (2012). The alarmin interleukin-33 drives protective antiviral CD8 (+). T cell responses. Science, 335, 984-9.   DOI   ScienceOn
20 Chackerian AA, Oldham ER, Murphy EE, et al (2007). IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. J Immunol, 179, 2551–5.   DOI
21 Dobrzanski MJ, Reome JB, Hylind JC, et al (2006). CD8-mediated type 1 antitumor responses selectively modulate endogenous differentiated and nondifferentiated T cell localization, activation, and function in progressive breast cancer. J Immunol, 177, 8191-201.   DOI
22 Gangemi S, Allegra A, Profita M, et al (2013). Decreased plasma levels of IL-33 could contribute to the altered function of Th2 lymphocytes in patients with polycythemia vera and essential thrombocythemia. Cancer Invest, 31, 212-3.   DOI   ScienceOn
23 Hu LA, Fu Y, Zhang DN, et al (2013). Serum IL-33 as a diagnostic and prognostic marker in non- small cell lung cancer. Asian Pac J Cancer Prev, 14, 2563-6.   과학기술학회마을   DOI   ScienceOn
24 Chen SF, Nieh S, Jao SW, et al (2013). The paracrine effect of cancer-associated fibroblast-induced interleukin-33 regulates the invasiveness of head and neck squamous cell carcinoma. J Pathol, 231, 180-9.   DOI   ScienceOn